ストックスクリーナーアプリを入手
0.479
8.57%
-0.0449
アフターアワーズ：
.50
0.021
+4.38%
前日終値:
$0.5239
開ける：
$0.5404
24時間の取引高:
1.10M
Relative Volume:
0.53
時価総額：
$31.32M
収益：
-
当期純損益:
$-41.95M
株価収益率:
-0.5771
EPS:
-0.83
ネットキャッシュフロー:
$-38.34M
1週間 パフォーマンス:
-18.81%
1か月 パフォーマンス:
-25.17%
6か月 パフォーマンス:
-34.58%
1年 パフォーマンス:
-90.44%
1日の値動き範囲:
$0.475
$0.55
1週間の範囲:
$0.475
$0.5993
52週間の値動き範囲:
$0.475
$5.8299
Elevation Oncology Inc Stock (ELEV) Company Profile
ELEV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ELEV
Elevation Oncology Inc
|
0.479 | 31.32M | 0 | -41.95M | -38.34M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Elevation Oncology Inc Stock (ELEV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-03 | 開始されました | William Blair | Outperform |
| 2024-05-31 | 開始されました | Piper Sandler | Overweight |
| 2024-05-14 | 開始されました | Stephens | Overweight |
| 2024-03-01 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-05-30 | アップグレード | SVB Securities | Market Perform → Outperform |
| 2021-12-23 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Elevation Oncology Inc (ELEV) 最新ニュース
Elevation Oncology Stock Hits 52-Week Low at $0.5 Amid Challenges By Investing.com - Investing.com South Africa
Elevation Oncology Stock Hits 52-Week Low at $0.5 Amid Challenges - Investing.com
Elevation Oncology (ELEV) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Elevation Oncology Inc’s (ELEV) Stock Is Harder To Predict Than You Think - Stocks Register
Elevation Oncology to Participate in Upcoming Investor Conferences - Citizentribune
Can Elevation Oncology's March Conference Appearances Reveal New Cancer Treatment Progress? - StockTitan
Brokerages Set Elevation Oncology, Inc. (NASDAQ:ELEV) PT at $7.20 - Defense World
Ovarian Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Aadi Bioscience Appoints David Dornan, PhD, as Chief Scientific Officer - Finansavisen
Former Elevation Oncology CSO Joins Aadi to Lead $100M ADC Portfolio Expansion - StockTitan
Elevation Oncology, Inc. (NASDAQ:ELEV) Shares Bought by SG Americas Securities LLC - Defense World
Are Elevation Oncology Inc (ELEV) shares a good deal now? - US Post News
Analysts Offer Predictions for ELEV Q2 Earnings - Defense World
Keeping an Eye on Elevation Oncology Inc (ELEV) After Insider Trading Activity - Knox Daily
Market Recap Check: Elevation Oncology Inc (ELEV)’s Negative Finish at 0.63, Up/Down -5.85 - The Dwinnex
Brokers Offer Predictions for ELEV Q1 Earnings - Defense World
Goldman Sachs Group Inc. Reduces Stake in Elevation Oncology Inc. - GuruFocus.com
JPMorgan Chase & Co. Raises Position in Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World
BlackRock, Inc. Increases Stake in Elevation Oncology Inc - GuruFocus.com
Elevation Oncology Inc (ELEV) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Understanding ELEV stock ratios for better investment decisions - US Post News
Elevation Oncology announces CSO departure By Investing.com - Investing.com South Africa
Elevation Oncology announces CSO departure - MSN
Elevation Oncology Chief Scientific Officer Announces ResignationOn January 29, 2025, Elevation Oncology, Inc. (NASDAQ: ELEV) received a communication from David Dornan, Ph.D., the company’s Chief Scientific Officer, regarding his decision to resign - Defense World
Elevation Oncology Announces CSO Resignation - TipRanks
Elevation Oncology, Inc. (NASDAQ:ELEV) Receives $7.20 Consensus PT from Analysts - Defense World
Vanguard Group Inc. Reduces Stake in Elevation Oncology Inc. - GuruFocus.com
Barclays PLC Has $43,000 Holdings in Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World
Agenus reports promising colorectal cancer treatment data - MSN
Elevation Oncology (NASDAQ:ELEV) Announces Program Updates and MilestonesOn January 13, 2025, Elevation Oncology, Inc. disclosed in a press release certain developments and upcoming milestones that are set to shape its trajectory in the coming mo - Defense World
Q4 Earnings Forecast for ELEV Issued By William Blair - Defense World
Esophageal Cancer Pipeline Assessment 2024: Therapies, Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | Oncolys BioPharma Inc, Genentech, OncoTherapy - The Globe and Mail
Oncolytics Bio (ONC-T) QuotePress Release - The Globe and Mail
Merck CEO talks medicines beyond the company's top cancer drug - MSN
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year - Lelezard
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year - Benzinga
Elevation Oncology advances gastric cancer trial, eyes new data in 2025 By Investing.com - Investing.com South Africa
Elevation Oncology advances gastric cancer trial, eyes new data in 2025 - Investing.com India
Elevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming Milestones - PR Newswire
Geode Capital Management LLC Increases Position in Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World
Elevation Oncology, Inc. (NASDAQ:ELEV) Shares Bought by Barclays PLC - Defense World
Why Elevation Oncology (ELEV) Is Among the Best Penny Stocks to Invest In According to Media? - Yahoo Finance
Analysts Set Elevation Oncology, Inc. (NASDAQ:ELEV) Price Target at $7.20 - Defense World
Elevation Oncology initiated with an Outperform at William Blair - MSN
Elevation Oncology, Inc. (NASDAQ:ELEV) Stock Position Boosted by State Street Corp - Defense World
Elevation Oncology (NASDAQ:ELEV) Now Covered by William Blair - Defense World
William Blair Initiates Coverage of Elevation Oncology (ELEV) with Outperform Recommendation - MSN
Elevation Oncology: Promising Cancer Therapies Earn Analyst Praise - Benzinga
This Denali Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Friday - Benzinga
Elevation Oncology Inc (ELEV) 財務データ
収益
当期純利益
現金流量
EPS
6.45%
1.23%
大文字化:
|
ボリューム (24 時間):